Wells Fargo’s Perspective Therapeutics CATX Stock Holding History

Wells Fargo’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$98K	Sell	23,491 -43,329	-65%	-$183K	﹤0.01%	5114
2025 Q4	$184K	Buy	66,820 +21,125	+46%	+$60.3K	﹤0.01%	5116
2025 Q3	$157K	Buy	45,695 +7,452	+19%	+$27.2K	﹤0.01%	5066
2025 Q2	$132K	Buy	38,243 +11,184	+41%	+$29.5K	﹤0.01%	5027
2025 Q1	$57.6K	Buy	27,059 +597	+2%	+$1.79K	﹤0.01%	5352
2024 Q4	$84.4K	Buy	26,462 +8,294	+46%	+$67.7K	﹤0.01%	5291
2024 Q3	$243K	Buy	18,168 +2,049	+13%	+$27.2K	﹤0.01%	4451
2024 Q2	$161K	Buy	16,119 +15,776	+4,599%	+$228K	﹤0.01%	4651
2024 Q1	$4.08K	Buy	343 +27	+9%	+$230	﹤0.01%	5923
2023 Q4	$1.27K	Sell	316 -3,146	-91%	-$8.86K	﹤0.01%	6177
2023 Q3	$9.47K	Buy	3,462 +35	+1%	+$163	﹤0.01%	5820
2023 Q2	$22.9K	Buy	3,427 +706	+26%	+$4.29K	﹤0.01%	5696
2023 Q1	$17.4K	Buy	2,721 +2,096	+335%	+$8.56K	﹤0.01%	5689
2022 Q4	$1.54K	Buy	625 +3	+0.5%	+$10	﹤0.01%	6070
2022 Q3	$1K	Sell	622 -1	-0.2%	-$3	﹤0.01%	6293
2022 Q2	$2K	Sell	623 -2	-0.3%	-$6	﹤0.01%	6300
2022 Q1	$2K	Buy	625 +10	+2%	+$36	﹤0.01%	6653
2021 Q4	$2K	Hold	615	–	–	﹤0.01%	6869
2021 Q3	$4K	Sell	615 -4	-0.6%	-$27	﹤0.01%	6424
2021 Q2	$5K	Sell	619 -1	-0.2%	-$9	﹤0.01%	6324
2021 Q1	$7K	Buy	620 +438	+241%	+$6.62K	﹤0.01%	6415
2020 Q4	$1K	Buy	182 +15	+9%	+$66	﹤0.01%	6324
2020 Q3	$1K	Buy	167 +122	+271%	+$795	﹤0.01%	6185
2020 Q2	$0	Hold	45	–	–	﹤0.01%	6306
2020 Q1	$0	Buy	+45	New	+$340	﹤0.01%	6220
2018 Q4	–	Sell	-1,000	Closed	-$5K	–	6398
2018 Q3	$5K	Hold	1,000	–	–	﹤0.01%	6112
2018 Q2	$5K	Hold	1,000	–	–	﹤0.01%	6077
2018 Q1	$4K	Hold	1,000	–	–	﹤0.01%	6091
2017 Q4	$4K	Hold	1,000	–	–	﹤0.01%	6077
2017 Q3	$5K	Hold	1,000	–	–	﹤0.01%	6011
2017 Q2	$6K	Hold	1,000	–	–	﹤0.01%	5870
2017 Q1	$6K	Hold	1,000	–	–	﹤0.01%	5983
2016 Q4	$6K	Hold	1,000	–	–	﹤0.01%	5909
2016 Q3	$7K	Sell	1,000 -300	-23%	-$2.29K	﹤0.01%	5834
2016 Q2	$11K	Hold	1,300	–	–	﹤0.01%	5636
2016 Q1	$12K	Buy	1,300 +300	+30%	+$2.36K	﹤0.01%	5634
2015 Q4	$9K	Hold	1,000	–	–	﹤0.01%	5754
2015 Q3	$14K	Hold	1,000	–	–	﹤0.01%	5631
2015 Q2	$15K	Hold	1,000	–	–	﹤0.01%	5689
2015 Q1	$16K	Hold	1,000	–	–	﹤0.01%	5461
2014 Q4	$15K	Hold	1,000	–	–	﹤0.01%	5470
2014 Q3	$17K	Hold	1,000	–	–	﹤0.01%	5370
2014 Q2	$31K	Hold	1,000	–	–	﹤0.01%	5160
2014 Q1	$22K	Hold	1,000	–	–	﹤0.01%	5191
2013 Q4	$5K	Hold	1,000	–	–	﹤0.01%	5353
2013 Q3	$7K	Hold	1,000	–	–	﹤0.01%	5199
2013 Q2	$5K	Buy	+1,000	New	+$5.39K	﹤0.01%	5213

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's CATX Position: Q1 2026 in Review

Wells Fargo reduced its Perspective Therapeutics (CATX) stake by 65% in Q1 2026, selling an estimated $183K and leaving 23,491 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #5114.

Wells Fargo first reported a position in CATX in Q2 2013 and has held it in 47 quarters since. The position peaked at $243K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

Wells Fargo held 23,491 shares of Perspective Therapeutics worth $98K as of Q1 2026.
Wells Fargo sold 43,329 Perspective Therapeutics shares in Q1 2026, an estimated $183K.
Perspective Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5114 holding.
Wells Fargo first reported a position in Perspective Therapeutics in Q2 2013 and has held it in 47 quarters since.
Wells Fargo's Perspective Therapeutics position peaked at $243K in Q3 2024.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.